Kamolwish Laoprasopwattana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kamolwish Laoprasopwattana has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Pornpimol Pruekprasert
2 shared publicationsPornsak Dissaneewate
2 shared publicationsPrayong Vachvanichsanong
2 shared publications- Alan Geater
Department of Epidemiology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
1 shared publication Malai Wongchanchailert
Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
1 shared publicationVichai Laosombat
Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
1 shared publication
Latest Publications
- 1 August 2010
- Published by Elsevier in The Journal of Pediatrics
- Vol. 157 (2) , 303-309
Outcome of Dengue Hemorrhagic Fever–Caused Acute Kidney Injury in Thai Children
- 1 August 2010
- Published by Elsevier in The Journal of Pediatrics
- Vol. 157 (2) , 303-309
Outcome of Dengue Hemorrhagic Fever–Caused Acute Kidney Injury in Thai Children
- 1 July 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (7) , 1337-1343
Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide
A knowledge of the causes and risk factors of fatal infection in childhood lupus nephritis (LN) patients treated with intravenous cyclophosphamide (IVCY) is important to enable optimal treatment. During an 11-year period (1996–2007), severe infection cases occurred in 31/84 (36.9%) patients with 64 infection episodes in our central referral institution in southern Thailand. Fatal infections occurred in 13/31 (41.9%) patients, most (11/13, 84.6%) during the first infective episode. The major causative organisms of the fatal infections were fungus and Gram-negative bacilli. Fatal infections were more likely to occur in patients with a prior history of treatment with pulse methylprednisolone and in patients with more active LN, as evidenced by the higher proteinuria and serum creatinine levels and lower hemoglobin and lymphocyte counts in this group than in patients with non-fatal infections. Multivariate analysis indicated that factors associated with fatal infection were prior treatment with pulse methylprednisolone [odds ratio (OR) 11.2, 95% confidence interval (CI) 1.9–61.0], renal failure (OR 5.9, 95% CI 1.0–34.8), and fungal infection (OR 23.9, 95% CI 1.9–298.2). Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.
- 1 July 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (7) , 1337-1343
Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide
A knowledge of the causes and risk factors of fatal infection in childhood lupus nephritis (LN) patients treated with intravenous cyclophosphamide (IVCY) is important to enable optimal treatment. During an 11-year period (1996–2007), severe infection cases occurred in 31/84 (36.9%) patients with 64 infection episodes in our central referral institution in southern Thailand. Fatal infections occurred in 13/31 (41.9%) patients, most (11/13, 84.6%) during the first infective episode. The major causative organisms of the fatal infections were fungus and Gram-negative bacilli. Fatal infections were more likely to occur in patients with a prior history of treatment with pulse methylprednisolone and in patients with more active LN, as evidenced by the higher proteinuria and serum creatinine levels and lower hemoglobin and lymphocyte counts in this group than in patients with non-fatal infections. Multivariate analysis indicated that factors associated with fatal infection were prior treatment with pulse methylprednisolone [odds ratio (OR) 11.2, 95% confidence interval (CI) 1.9–61.0], renal failure (OR 5.9, 95% CI 1.0–34.8), and fungal infection (OR 23.9, 95% CI 1.9–298.2). Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (8) , 595-606
CLINICAL OUTCOME OF FEBRILE NEUTROPENIA IN CHILDREN WITH CANCER USING CEFTAZIDIME AND AMINOGLYCOSIDES
To determine treatment outcome using ceftazidime–aminoglycosides in febrile neutropenic children with cancer, the authors conducted a prospective cohort study in 216 episodes. Early and complete responses to antibiotics were 108/216 (50.0%) and 133/216 (61.6%) episodes, respectively. Death, a modification of antibiotic(s), and resistance to ceftazidime were 2/118 (1.7%), 73/216 (33.8%), and 4/216 (1.9%) episodes, respectively. Primary bacteremia and emerging bacteremia during treatment were 20/216 (9.3%) and 5/216 (2.3%) episodes. Ceftazidime–aminoglycosides was found to be a reasonable initial treatment of febrile neutropenia in the authors’ institution. Imipenem is considered in patients who have clinical sepsis and who fail to respond to initial treatment.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (8) , 595-606
CLINICAL OUTCOME OF FEBRILE NEUTROPENIA IN CHILDREN WITH CANCER USING CEFTAZIDIME AND AMINOGLYCOSIDES
To determine treatment outcome using ceftazidime–aminoglycosides in febrile neutropenic children with cancer, the authors conducted a prospective cohort study in 216 episodes. Early and complete responses to antibiotics were 108/216 (50.0%) and 133/216 (61.6%) episodes, respectively. Death, a modification of antibiotic(s), and resistance to ceftazidime were 2/118 (1.7%), 73/216 (33.8%), and 4/216 (1.9%) episodes, respectively. Primary bacteremia and emerging bacteremia during treatment were 20/216 (9.3%) and 5/216 (2.3%) episodes. Ceftazidime–aminoglycosides was found to be a reasonable initial treatment of febrile neutropenia in the authors’ institution. Imipenem is considered in patients who have clinical sepsis and who fail to respond to initial treatment.